FY2025 · ended Dec 31, 2025 · Revenue $311.71M, +617.0% YoY · Filed Mar 5, 2026
Cormedix Inc. (CRMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $311.7 million and net income of $163.1 million. Free cash flow was $172.8 million.
Revenue (TTM)
$462.25M
+280.5% vs year-ago TTM
Net income (TTM)
$187.17M
+265.9% vs year-ago TTM
Operating cash flow (TTM)
$253.94M
+733.6% vs year-ago TTM
Free cash flow (TTM)
$250.42M
+723.5% vs year-ago TTM
EPS (TTM)
$16.93
+106.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
79.05M
+21.3% vs prior year
Net cash
$150.91M
FY 2025
Operating margin
47.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1410098
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | — | $65,408 | $190,936 |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M | -$29.4M |
| Net income | $163.1M | -$17.9M | -$46.3M | -$29.7M | -$28.2M |
| Diluted EPS | $2.04 | -$0.30 | -$0.91 | -$0.74 | — |
| Operating cash flow | $175.0M | -$50.6M | -$38.4M | -$24.4M | -$21.2M |
| Free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M | -$22.6M |
| Total assets | $826.1M | $118.8M | $82.1M | $62.0M | $68.9M |
| Total liabilities | $420.8M | $34.2M | $11.9M | $7.0M | $6.1M |
| Stockholders' equity | $405.3M | $84.7M | $70.1M | $55.1M | $62.8M |
| Cash and investments | $155.2M | $51.7M | $76.0M | $58.8M | $65.5M |
| Total debt | $4.3M | $517,000 | $668,000 | $803,000 | $924,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Other events
|
Jul 2, 2026 | Jun 29, 2026 |
All 1003 Cormedix Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.